摘要
目的:研究整合素α5β1 在非小细胞肺癌(non -small cell lung cancer,NSCLC)组织中的表达以及与临床病理特征的关系。方法:用免疫组化SP法检测53例NSCLC组织及12 例正常肺组织的石蜡标本中α5β1 的表达情况。结果:整合素α5β1 在NSCLC组织中的表达(58. 49%)明显高于正常肺组织( 16 .67%),差异有统计学意义,P=0 .009;α5β1 的表达与病理分级负相关,高、中、低分化NSCLC 组织α5β1 的阳性率分别是28. 57%、68 .18%和70 .59%,病理分级越低,表达越高,差异有统计学意义,P=0 .031;α5β1 表达升高与淋巴结转移、临床分期有关,α5β1 在淋巴结转移阳性的NSCLC组织中的表达(67 .50%)高于淋巴结转移阴性组表达(30 .77%),差异有统计学意义,P=0 020,α5β1 在Ⅱ、Ⅲ期NSCLC组织中的表达(64. 29%、75 00%)高于Ⅰ期(30. 77%),差异有统计学意义,P=0 .042。结论:α5β1 高表达可能与NSCLC的恶性生物学特性有关,α5β1 在NSCLC的发生、发展中可能起了一定的作用。
OBJECTIVE:To study the expression and its clinical significance of integrin α_5β_1 in non-small cell lung cancer(NSCLC). METHODS:The expression of integrinα_5β_1 was examined by immunohistochemistry technology in 53 cases of NSCLC and 12 normal lung tissues. RESULTS:The expression of integrin α_5β_1 in NSCLC tissues (58.49%) was a significantly higher than that of normal lung tissues (16.67%), P =0.009. The level of expression for integrin α_5β_1 in high histological differentiation (28.57%) was significantly lower than that in middle and low histological differentiation (68.18% and 70.59% respectively), P =0.031. There was a significant difference between NSCLC with positive lymph node metastasis (67.50%) and that with negative lymph node metastasis (30.77%), P =0.020. There also existed a significant difference among clinical stages (the positive rate of Ⅰ,Ⅱ,Ⅲ staging was 30.77%, 64.29% and 75.00%, respectively), P =0.042. CONCLUSION:The expression of integrin α_5β_1 is significantly correlated with carcinogenesis, differentiation and lymph node metastasis, and may play an important role in prognosis of NSCLC.
出处
《肿瘤防治杂志》
2005年第8期593-595,共3页
China Journal of Cancer Prevention and Treatment
